Neoplasms, Plasma Cell: all 2,314 studies

Page 6 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.

• Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationCompletedNCT01810588Phase 2Results posted
• A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple MyelomaCompletedNCT01801436Phase 3Results posted
• Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01794520Phase 1/2Results posted
• Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideCompletedNCT01794039Phase 2Results posted
• Intervention for Symptom Burden During Maintenance Therapy for Multiple MyelomaCompletedNCT01793051Phase 2Results posted
• Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving BortezomibTerminatedNCT01783522Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)CompletedNCT01782963Phase 2Results posted
• Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic AcidTerminatedNCT01772719Not applicableResults posted
• Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaCompletedNCT01755975Phase 1/2Results posted
• Bendamustine + Pomalidomide + Dex in R/R Multiple MyelomaActive, not recruitingNCT01754402Phase 1/2Results posted
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01734928Phase 3Results posted
• Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple MyelomaCompletedNCT01731886Phase 4Results posted
• Velcade + Cyclophosphamide in Newly Diagnosed Multiple MyelomaTerminatedNCT01729338Phase 2Results posted
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01729091Phase 2Results posted
• Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma PatientsTerminatedNCT01720043Phase 2Results posted
• Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01718743Phase 2Results posted
• Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01712789Phase 3Results posted
• Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell TransplantCompletedNCT01706666Phase 2Results posted
• A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01698801Phase 2Results posted
• Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensTerminatedNCT01695330Phase 2Results posted
• Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationCompletedNCT01690143Phase 1/2Results posted
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple MyelomaCompletedNCT01677858Phase 1/2Results posted
• Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01676961Phase 2Results posted
• Lenalidomide Maintenance Therapy for Multiple MyelomaTerminatedNCT01675141Phase 2Results posted
• A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
• QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01670994Phase 1/2Results posted
• Carfilzomib and Stem Cell Transplant for Plasma Cell MyelomaTerminatedNCT01658904Phase 1/2Results posted
• Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell TransplantationTerminatedNCT01653418Phase 2Results posted
• Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)CompletedNCT01651039Phase 2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01646762Phase 2Results posted
• Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01645930Phase 1Results posted
• Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaCompletedNCT01632150Phase 2Results posted
• UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple MyelomaCompletedNCT01621672Phase 3Results posted
• Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01605032Phase 2Results posted
• A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)CompletedNCT01602224Phase 2Results posted
• Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma PatientsCompletedNCT01568866Phase 3Results posted
• A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01564537Phase 3Results posted
• Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple MyelomaCompletedNCT01556438Phase 1Results posted
• Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior TreatmentTerminatedNCT01548573Phase 2Results posted
• Collection of Transplant Stem Cells for Plasma Cell MyelomaCompletedNCT01547806Phase 2Results posted
• 1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple MyelomaCompletedNCT01541644Not applicableResults posted
• Velcade (Bortezomib) Consolidation After TransplantCompletedNCT01539083Phase 3Results posted
• CP-751,871 Treatment For Patients With Multiple MyelomaCompletedNCT01536145Phase 1Results posted
• High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT01534143Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)CompletedNCT01531998Phase 1/2Results posted
• Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2Results posted
• Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT01484626Phase 1/2Results posted
• Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple MyelomaTerminatedNCT01484314Phase 2Results posted
• A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple MyelomaCompletedNCT01484275Phase 2Results posted
• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT01478581Phase 2Results posted
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01478048Phase 2Results posted
• Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide MaintenanceCompletedNCT01463670Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin DiseaseCompletedNCT01458288Phase 2Results posted
• A Study of DKN-01 in Multiple Myeloma or Advanced Solid TumorsCompletedNCT01457417Phase 1Results posted
• Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedNCT01447914Phase 2Results posted
• Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaCompletedNCT01441973Phase 2Results posted
• Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple MyelomaTerminatedNCT01438177Phase 2Results posted
• Pomalidomide in Combination With High Dose Dexamethasone and Oral CyclophosphamideCompletedNCT01432600Phase 1/2Results posted
• Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing TransplantCompletedNCT01426828Phase 2Results posted
• A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaCompletedNCT01421186Phase 1/2Results posted
• A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01413178Phase 3Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma PatientsCompletedNCT01402284Phase 2Results posted
• Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal FunctionCompletedNCT01393964Phase 1Results posted
• Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01383928Phase 1/2Results posted
• MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationCompletedNCT01380145Phase 1Results posted
• Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple MyelomaCompletedNCT01380106Phase 2Results posted
• Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple MyelomaTerminatedNCT01374217Phase 2Results posted
• Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01355705Phase 1/2Results posted
• Redirected Auto T Cells for Advanced MyelomaCompletedNCT01352286Phase 2Results posted
• Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01351623Phase 2Results posted
• Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two StepsTerminatedNCT01350258Phase 1/2Results posted
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorCompletedNCT01350245Phase 2Results posted
• Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete RemissionCompletedNCT01349569Phase 2Results posted
• Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01348919Phase 1/2Results posted
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaCompletedNCT01345019Phase 3Results posted
• Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01335685Phase 1/2Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01335399Phase 3Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaCompletedNCT01324947Phase 3Results posted
• Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple MyelomaCompletedNCT01319422Phase 2Results posted
• Bortezomib and Bendamustine to Treat Relapsed/Refractory MyelomaTerminatedNCT01315873Phase 2Results posted
• UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple MyelomaCompletedNCT01313897Phase 2Results posted
• A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion StudyCompletedNCT01311687Phase 3Results posted
• Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)TerminatedNCT01303965Phase 1/2Results posted
• A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01302392Phase 3Results posted
• A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic MyelomaTerminatedNCT01302366Phase 2Results posted
• Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With LenalidomideTerminatedNCT01301963Phase 3Results posted
• Evaluation of the Spectra Optia® Mononuclear Cell Collection ProcedureCompletedNCT01292486Not applicableResults posted
• Velcade Consolidation Bone StudyCompletedNCT01286077Phase 2Results posted
• Prevention of Treatment Induced Neuropathy in Multiple MyelomaCompletedNCT01283997Phase 2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• A Phase II Trial of Anti-KIR in Smoldering Multiple MyelomaTerminatedNCT01248455Phase 2Results posted
• Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01246063Phase 1/2Results posted
• Combination Immunotherapy and Autologous Stem Cell Transplantation for MyelomaCompletedNCT01245673Phase 2Results posted
• Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose DexamethasoneCompletedNCT01241292Phase 1Results posted
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01239797Phase 3Results posted
• Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple MyelomaTerminatedNCT01239368Phase 1/2Results posted
• High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk MyelomaCompletedNCT01237951Phase 2Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
• A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01217957Phase 1/2Results posted

← Neoplasms, Plasma Cell overview